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Background
Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia
and lymphoblastic lymphoma. Our aim was to determine whether dexamethasone results in a
better outcome than prednisolone.
Design and Methods
Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were random-
ized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone
8 mg/m2 or prednisolone 60 mg/m2. Those who reached complete remission were given two
courses of consolidation therapy with high-dose cytarabine and mitoxantrone and methotrex-
ate and asparaginase. Subsequently patients younger than 50 years, with a suitable donor, were
to undergo allogeneic stem cell transplantation, whereas the others were planned to receive
either an autologous stem cell transplant or high-dose maintenance chemotherapy with pro-
phylactic central nervous system irradiation. Randomization was done with a minimization
technique. The primary endpoint was event-free survival and the analyses was conducted on
an intention-to-treat basis. 
Results
Between August 1995 and October 2003, 325 patients between 15 to 72 years of age were ran-
domized to receive either dexamethasone (163 patients) or prednisolone (162 patients). After
induction and the course of first consolidation therapy, 131 (80.4%) patients in the dexametha-
sone group and 124 (76.5%) in the prednisolone group achieved complete remission. No sig-
nificant difference was observed between the two treatment groups with regards to 6-year
event-free survival rates (±SE) which were 25.9% (3.6%) and 28.7% (3.5%) in the dexametha-
sone and prednisolone groups, respectively (P=0.82, hazard ratio 0.97; 95% confidence inter-
val, 0.75-1.25). Disease-free survival after complete remission was also similar in the dexam-
ethasone and prednisolone groups, the 6-year rates being 32.3% and 37.5%, respectively (haz-
ard ratio 1.03; 95% confidence interval 0.76-1.40). The 6-year cumulative incidences of relapse
were 49.8% and 53.5% (Gray’s test: P=0.30) while the 6-year cumulative incidences of death
were 18% and 9% (Gray’s test: P=0.07). 
Conclusions
In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lym-
phoma, treatment with dexamethasone did not show any advantage over treatment with pred-
nisolone. (ClinicalTrials.gov Identifier: NCT00002700)
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Introduction
Corticosteroids are a standard component of treatment
for acute lymphoblastic leukemia (ALL) and lymphoblas-
tic lymphoma (LBL). The response to corticosteroids dur-
ing the pretreatment phase is essential in defining the risk
of ALL and treatment outcome, especially in children.1-3
Corticosteroids are also part of the induction and the
maintenance therapy in adults.4,5 Dexamethasone is 6.5
times more potent than prednisolone as measured by con-
ventional glucocorticoid activity, but it shows a 16-fold
gain in potency against lymphoblasts in vitro, suggesting
that it might be a more active corticosteroid in the treat-
ment of ALL.6,7 The better penetration in the central nerv-
ous system (CNS)8 and the enhanced lymphoblastic cyto-
toxicity might explain the lower bone marrow relapse
rate, the lower CNS relapse rate and the advantage in
event-free survival recorded in children receiving dexam-
ethasone.9-11 However, attempts to increase the
antileukemic effect of dexamethasone by increasing its
dose have been associated with increased toxicity and
early deaths, mostly due to severe infections.12
Since a comparison of dexamethasone and prednisolone
is not available for adult patients with ALL/LBL we
assessed and compared the antileukemic activity and tox-
icity of dexamethasone and prednisolone in this setting in
a randomized, phase III trial.
Design and Methods 
Previously untreated adult patients with ALL or LBL  were eli-
gible for inclusion in this trial, which was approved by the
EORTC Protocol Review Committee and by the Ethics
Committees of the participating institutions. The study was con-
ducted in 20 European centers, in accordance with the
Declaration of Helsinki. The study design is presented in Figure
1. Inclusion criteria were absence of prior malignancy except
those originating in the skin (non-melanoma) or those considered
to be cured, absence of severe cardiac, pulmonary, neurological
or metabolic disease, adequate liver function (bilirubin < 2
mg/dL) and renal function (creatinine < 2 mg/dL) (unless the dys-
function was considered to be due to leukemic involvement), and
no infection by human immunodeficiency virus. All participants
gave their informed consent to inclusion in the study.
For remission induction patients were randomized to receive
dexamethasone or prednisolone together with chemotherapy.
The first randomization was prospectively stratified by white
blood cell count, diagnosis (ALL versus LBL), age (15-19, 20-34,
35-60, and >60 years old) and center using a minimization tech-
nique. Patients who achieved complete or good partial remission
were eligible to receive a course of intensive consolidation with
high-dose cytarabine and mitoxantrone (HAM). All patients in
complete remission after HAM consolidation underwent  treat-
ment with two courses of consolidation consisting of high-dose
methotrexate and asparaginase (MA). After MA consolidation
patients 50 years of age or less with a sibling donor were assigned
to undergo allogeneic hematopoietic stem cell transplantation
(SCT), while patients without a sibling donor who were 20 to 60
years of age were randomized to undergo either autologous SCT
followed by low-dose maintenance chemotherapy (arm A) or
receive high-dose maintenance chemotherapy with prophylactic
CNS irradiation (arm B). The maintenance regimens both con-
tained vincristine and adriamycin and either dexamethasone
(VAD) or prednisolone (VAP). Patients were eligible for the sec-
ond randomization if the following criteria were fulfilled: com-
plete remission was achieved after induction and/or consolida-
tion treatment, allogeneic SCT was not planned (see below),
absence of very high features (mature B-cell phenotype, acute
undifferentiated leukemia or Philadelphia chromosome-positive
ALL), absence of severe cardiac, pulmonary, neurological and
metabolic disease, adequate liver function (bilirubin < 2 mg/dL)
and  renal function (creatinine <2 mg/dL), suitable bone marrow
function in terms of  in vitro growth of colony-forming units –
granulocyte/macrophage (> 2¥104 cells/kg) and cellularity (>
2¥108 nucleated cells/kg), with negativity for human immunode-
ficiency virus after completion of MA consolidation, and signed
informed consent.
Patients between 15 and 19 years of age, without a donor (see
below) were eligible for the second randomization if at least one
of the following were present: initial white blood cell count
greater than 30¥109/L,  initial CNS or other extramedullary local-
ization of disease, or complete remission achieved later than day
28. The remaining younger patients without high risk features or
patients older than 60 years were assigned to arm B of the study.
Patients less than 50 years old with an HLA-matched (genotypi-
cally and phenotypically) family donor or with a family donor
mismatched for one HLA locus (A, B, or DR) or with a matched
unrelated donor (optional), together with all the conditions men-
tioned for the second randomization were eligible for allogeneic
SCT. The schedules and doses of cytotoxic drugs and chemother-
apy courses are presented in Table 1. 
The recommended conditioning regimen for allogeneic and
autologous SCT was cyclophosphamide (60 mg/kg on 2 consec-
utive days) and total body irradiation fractionated over 3 days,
for a total dose of 1200 cGy. Graft-versus-host disease prophylax-
is in most centers consisted of cyclosporine and a short course of
methotrexate.13 T-cell depletion of the allogeneic graft was per-
formed in 13 cases by elutriation or by alemtuzumab “in the
bag”.14
Complete remission was defined as a morphologically normal
marrow with less than 5% of blasts and normal peripheral blood
and differential counts. Partial remission was defined as a treat-
ment response with reduction of more than 50% of the leukemic
marrow blasts present at diagnosis, and/or hypoplastic marrow
and/or cytopenia of peripheral blood counts. Refractory patients
were defined as patients who did not reach complete remission
after induction and first intensive consolidation. Among patients
who reached complete remission, relapse was defined by the
presence of more than 5% blasts in the bone marrow. A diagno-
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Figure 1. EORTC ALL-4 protocol: study design. Dxm: dexametha-
sone; PDN: prednisolone; CR: complete remission; PR: partial
remission; HAM: high-dose cytarabine and mitoxantrone; MA:
methotrexate and asparaginase; auto: autologous; allo: allogeneic;
SCT: stem cell transplantation.
sis of extramedullary relapse was based on tissue diagnosis in the
case of clinical symptoms or organ or tissue infiltration and cere-
brospinal fluid cytology in the case of meningeal relapse. Risk
factors were defined according to Gökbuget et al.15
Statistical analysis
The ALL-4 trial was a 2x2 factorial design, phase III study eval-
uating efficacy and toxicity of dexamethasone versus pred-
nisolone and of autologous SCT followed by low-dose mainte-
nance versus prophylactic CNS irradiation with high-dose main-
tenance. The primary end-point for the comparison of dexam-
ethasone and prednisolone was event-free survival, which was
calculated as the time from the date of complete remission until
the date of first relapse or of death in first complete remission;
patients who did not reach complete remission after induction
were considered to have had events at time 0. By definition all
patients who died in complete remission were considered as
cases of treatment-related mortality. The duration of survival was
calculated from the date of randomization until the date of death;
patients still alive were censored at their last follow-up. For the
comparison of second randomization (autologous SCT and low-
dose maintenance versus prophylactic CNS irradiation and high-
dose maintenance) the starting point was the date of randomiza-
tion. This study was powered to detect a 15% treatment differ-
ence in the 3-year event-free survival rates (45% in dexametha-
sone group), corresponding to a hazard ratio of 0.66. A minimum
of 308 patients had to be randomized, of whom 192 had to be
followed until an event (two-sided α=5%, b=20%).
Actuarial curves were calculated according to the Kaplan-
Meier technique.16 The standard errors (SE) of the estimates were
computed using the Greenwood formula.16 The estimates of the
incidence of relapse and of death in complete remission, and their
corresponding standard errors, were obtained using the cumula-
tive incidence method, in which the risks of death in complete
remission and of relapse were considered as competing risks.16
The statistical significance of differences between actuarial
curves was tested using a two-tailed log-rank test,16 whereas
Gray’s test was used for the cumulative incidences.17 A Cox pro-
portional hazards model was employed to obtain the estimate
and the 95% confidence interval of the hazard ratio of the instan-
taneous event rate in one group compared with in another group,
as specified by a given variable, and the Wald test was used to
determine the prognostic significance.16 This model was also
used to determine the relative prognostic importance of several
factors. The database was frozen in August 2007. SAS 9.1 statis-
tical software (SAS Institute Inc, Cary, NC, USA) was used for
the statistical computations.
Results
Patients’ characteristics according  
to the first randomization
Between August 1995 and October 2003, 325 patients
from 15 to 72 years of age with ALL or LBL were regis-
tered in the ALL-4 study and randomized to receive either
dexamethasone or prednisolone. The characteristics of the
patients, divided according to treatment arm, are present-
ed in Table 2. 
The distributions of age and sex were similar in both
groups; 94% of patients had ALL. Initial CNS infiltration
was found in 72 patients and its incidence (22%) was sim-
ilar in the two treatment groups. B-lineage ALL was docu-
mented in 65% of the patients by immunophenotyping.
The majority of the patients (70%) fulfilled the criteria for
high-risk ALL. In 215 (66%) patients cytogenetic analysis
was successful. Among these patients, cytogenetic analy-
sis was normal in 54 (25%), while Philadelphia chromo-
some-positive ALL was documented in 23% of them. The
median follow-up was 6.6 years with a range from 0.5 to
11.7 years.  
Overall, 77 (23%) patients were allografted in first com-
plete remission and 78 (24%) were randomized for the
second question of the trial. The impact of the first ran-
domization (dexamethasone versus prednisolone) on the
last step of treatment was quite minor. Failure, relapse and
toxicity were the main reasons for stopping therapy and
30% of patients finished therapy according to the proto-
col. 
Treatment outcome
Table 3 summarizes the treatment outcome according
to the first randomization. The complete remission rate
was similar in both groups. Overall, 131 (80.4%) patients
in the dexamethasone group and 124 (76.5%) patients in
the prednisolone group achieved a complete remission
after induction therapy and the first course of consolida-
tion. 
There was no difference between the groups treated
with dexamethasone or prednisolone with respect to pri-
mary resistance, hypoplasia or early death. The remission
rate for patients with CNS infiltration was practically
identical for both groups: six out of eight patients in the
Dexamethasone versus prednisolone for adult ALL/LBL
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Table 1. Scheme of the ALL-4 protocol. 
dexamethasone group compared with six out of nine
patients in the prednisolone group. 
Among patients who reached complete remission, the
relapse rate was also similar for both groups: 48.9% for
the dexamethasone group and 52.4% for the prednisolone
group. No significant difference was observed between
the two treatment groups regarding event-free survival:
the 6-year event-free survival rate was 25.9% in the dex-
amethasone group and 28.7% in the prednisolone group
(P=0.82; hazard ratio 0.97; 95% confidence interval 0.75-
1.25) (Figure 2A).
Similarly, no significant difference was observed
between the two treatment groups regarding overall sur-
vival: the 6-year survival rate was 30.6% in the dexam-
ethasone group and 35.2% in the prednisolone group
(P=0.45; hazard ratio 1.11; 95% confidence interval, 0.85-
1.45) (Figure 2B). 
As indicated in Figure 2C, disease-free survival was sim-
ilar in the dexamethasone group and in the prednisolone
group: the 6-year disease-free survival rate from complete
remission was 32.3% in the dexamethasone group and
37.5% in the prednisolone group (P=0.83; hazard ratio
1.03; 95% confidence interval, 0.76-1.40). The 6-year
cumulative incidence (±SE) of relapse was 49.8% (±4.5%)
in the dexamethasone group and 53.5% (±4.6%) in the
prednisolone group (Gray’s test: P=0.30), whereas the 6-
year cumulative incidence (±SE) of death was 18.0%
(±3.4%) and 9.0% (±2.6%), respectively (Gray’s test:
P=0.07). 
A trend for shorter overall survival from complete
remission was found for patients in the dexamethasone
group compared to those in the prednisolone group
(P=0.18; hazard ratio 1.24; 95% confidence interval, 0.90-
1.70), with the 6-year overall survival rates being 35.2%
versus 43.7%, respectively (Figure 2D). Using a Cox model,
the trend in disfavor of dexamethasone persisted: the
comparison of overall survival for patients in the dexam-
ethasone and prednisolone groups, adjusted for initial
white blood cell count and age, yielded a P=0.11; hazard
ratio, 1.30; and 95% confidence interval, 0.94-1.79.
Toxicity
Table 4 shows the grade III-IV toxicities, divided accord-
ing to steroid randomization group, observed during induc-
tion therapy and consolidation. 
B. Labar et al.
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Table 2. Patients’ characteristics according to the first randomization. 
Dexamethazone Prednisolone 
n=163  (100%) n=162 (100%)
Sex (n, %)
Male 90 (55) 97 (60)
Female 73 (45) 65 (40)
Age (years)
Median (range) 32 (15-68) 33.5 (15-72)
15 to <20 (n, %) 30 (18) 30 (19)
20 to <35 (n, %) 57 (35) 55 (34)
35 to <61 (n, %) 68 (42) 69 (43)
61 (n, %) 8 (5) 8 (5)
Disease (n, %)
Acute lymphoblastic leukemia 153 (94) 152 (94)
Lymphoblastic lymphoma 10 (6) 10 (6)
White blood cell count (¥109/L)
Median (range) 11.4 (0.8-373) 13.6 (0.9-934)
< 30 (n, %) 109 (67) 107 (66)
30 to ≤ 100 (n, %) 31 (19) 32 (20)
> 100 (n, %) 23 (14) 23 (14)
Immunophenotype (n, %)
B-lineage (n, %) 106 (65) 111 (69)
T-lineage (n, %) 50 (31) 40 (25)
Biphenotypic (n, %) 5 (3) 4 (2)
Acute undifferentiated leukemia (n, %) 2 (1) 6 (4)
Unknown (n, %) 0 (0) 1 (1)
Cytogenetics (n, %)
Failure (n, %) 19 (12) 15 (9)
Normal karyotype (n, %) 27 (17) 28 (17)
Good risk (n, %)* 31 (19) 23 (14)
Presence of t(4;11) (n, %) 2 (1) 5 (3)
Presence of t(9;22)** (n, %) 29 (18) 28 (17)
Other bad risk*** (n, %) 18 (11) 13 (8)
Other abnormalities (n, %) 6 (4) 5 (3)
Unknown (n, %) 35 (22) 41 (25)
Extramedulary involvement (n, %)
No (n, %) 117 (72) 115 (71)
CNS (n, %) 37 (23) 35 (22)
Other involvement (n, %) 9 (6) 12 (7)
*Good risk: hyperdiploidy, presence of 9p-, t(10;14); ** and/or presence of BCR/ABL,
detected by RT-PCR; ***Other bad risk cytogenetics: hypodiploidy (<30), presence of
t(8;14), complex abnormalities (≥ 5 chromosomal abnormalities, excluding those
patients with established translocations); NN: normal karyotype.
Table 3. Treatment outcome for all patients and for patients random-
ized to receive dexamethasone or prednisolone.
Variable Dexamethazone Prednisolone
n=163 (%) n= 162 (%)
Overall response 
Complete response 131 (80.4) 124 (76.5)
Partial response 5 (3.1) 11 (6.8)
Resistance 6 (3.7) 7 (4.3)
Hypoplasia 5 (3.1) 4 (2.5)
Early death 14 ( 9.8) 13 (8.0)
Not evaluable   2 ( 1.2) 3 (1.9)
Disease-free status
Continuous complete remission 43 [32.8] 46 [37.1]
Relapse 64 [48.9] 65 [52.4] 
Bone marrow only 44 [33.6] 48 [38.7]
CNS relapse only 3 [2.3] 5 [4.0]
CNS+bone marrow 6 [4.6] 5 [4.0]
Other 11 [8.4] 7 [5.8]
Transplant-related mortality* 24 [18.3] 13 [10.5]
Infection 11 7
Hemorrhages 1 3
Graft-versus-host disease 5 1
Other 7 2
Survival status
Alive 50 (30.7) 58 (35.8) 
Dead 113 (69.3) 104 (64.2) 
Leukemia 51 (31.3) 56 (34.6)
Toxicity 43 (26.4) 31 (19.1)
Both 8 (4.9) 7 (4.3)
Other 11 (6.7) 10 (6.2)
*: after allogeneic SCT: 14 (2 in Philadelphia-positive patients) versus 9 (1 in a
Philadelphia-positive patient).
The incidence of severe toxicities was similar among
patients randomized to either dexamethasone or pred-
nisolone treatment. A trend for a higher incidence of hyper-
glycemia was documented in the dexamethasone group. In
both treatment arms leukemia was the main cause of death
(data not shown). Among the patients who reached complete
remission, 18% in the dexamethasone group and 10.5% in
the prednisolone group died without relapse. Most of the
mortality was related to allogeneic SCT. The predominant
causes of death following allografting were infections,
severe graft-versus-host disease and organ toxicity. 
Discussion 
In the context of the investigation of steroid therapy for
adult ALL/LBL in the ALL-4 trial of the EORTC-Leukemia
Group, dexamethasone treatment did not show any ben-
efit on treatment outcome compared to prednisolone. The
antileukemic efficacy of dexamethasone and prednisolone
did not seem to differ. Thus, the results of the ALL-4 study
do not support the experience from several pediatric stud-
ies using historical controls or of two large prospectively
randomized clinical trials18,19 showing that patients receiv-
ing dexamethasone have a better outcome. Data indicat-
ing that dexamethasone penetrates better into the CNS
and has enhanced activity against disease9-11 could not be
confirmed in the ALL-4 trial.
The reasons for the non-superiority of dexamethasone
in our trial might be the type of patient treated (adults
rather than children) and the doses of dexamethasone and
prednisolone. The Children’s Cancer Group trial CCG-
192218 compared the role of dexamethasone and pred-
nisolone therapy in standard-risk ALL during induction,
consolidation and maintenance therapy (in patients < 10
years of age and with white blood cell counts <50¥109/L).
Patients randomized to the dexamethasone arm received
a daily dose of 6 mg/m2 for 28 days for a total of 168
mg/m2 in the induction phase, 120 mg/m2 during consoli-
dation, 210 mg/m2 during the delayed intensification
(note: also in the prednisolone arm) and 150 mg/m2 during
the maintenance phase. The daily dose of prednisolone in
induction was 40 mg/m2 and the planned total dosages
were 1160 mg/m2 during consolidation, 800 mg/m2 during
delayed intensification and 600 mg/m2 per maintenance
cycle. There was a significant difference in event-free sur-
Dexamethasone versus prednisolone for adult ALL/LBL
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Figure 2. The 6-year event-free survival (A) and overall survival (B), disease-free survival from complete remission  (C) and survival from com-
plete remission (D)  according to randomization to dexamethasone or prednisolone. N = total number of patients; O = observed number of
events; SE: standard error (%). 
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vival at 6 years between the dexamethasone group and
the prednisolone group (85% versus 77%, respectively),
but no difference in overall survival. Furthermore there
was a significant difference in isolated CNS relapse rate
and a trend to a difference in bone marrow relapse rate in
favor of the dexamethasone arm. Patients using dexam-
ethasone more often developed myopathy and hyper-
glycemia. No difference was found in the frequency or
severity of infection between the two treatment arms. 
In the ALL 97/99 trial of the MRC Childhood Leukemia
Working Party19 standard- and high-risk ALL patients (very
high-risk patients were excluded) were randomized to
receive either prednisolone or dexamethasone. They had
to receive a daily dose of dexamethasone of 6.5 mg/m2 for
28 days, corresponding to a total dose of 182 mg/m2 in
induction, 130 mg/m2 as interim maintenance, 140 mg/m2
during delayed intensification (note: also in the pred-
nisolone arm) and 97.5 mg/m2 each 12-week cycle as con-
tinuation therapy. In the prednisolone arm, the daily dose
of prednisolone was 40 mg/m2 and the total dosages were
1160 mg/m2 during consolidation, 400 mg/m2 during
delayed intensification and 600 mg/m2 per maintenance
cycle.
In this study too, there was a significant difference in
event-free survival in favor of the dexamethasone arm
(being 84% versus 76% at 5 years), but not in terms of 5-
year overall survival. The risk of CNS relapse was signifi-
cantly decreased but not that of bone marrow relapse.
There was a significant excess of overall toxicity in the
dexamethasone group due to behavioral problems,
myopathy and severe osteopenia, as well as a decreased
quality of life20 but not due to infections.
The ALL-4 trial included only patients over the age of 18
years. The majority of patients had high-risk ALL/LBL. A
total dose of 112 mg/m2 dexamethasone was given during
induction and a total dose of 320 mg (corresponding to
160-200 mg/m2) during the maintenance phase. The total
prednisolone dosages were 840 mg/m2 and 800 mg
(approximately 400-450 mg/m2), respectively. We did not
find differences in disease-free or overall survival, or in
relapse incidence and pattern, while a trend to higher tox-
icity was observed in the dexamethasone arm. 
The adult patients in our trial received only 65-70% of
the dexamethasone dose reported in the childhood ALL
trials18,19 but they also received a lower total dose of pred-
nisolone (approximately 70%) than that given to the chil-
dren. In addition, the type of patients treated in the ALL-
4 trial differed greatly from that in the pediatric trials with
respect to age and to the percentage of high-risk patients.
The difference in efficacy of dexamethasone in children
and adult ALL could also be related to a different biology
of the disease in children and adults,21 and the different
intensity of treatment protocols used.22 More aggressive
chemotherapy, together with a better prognosis of ALL in
children,23,24 could be of importance in predicting better
response to steroids. 
The authors of a pilot trial (06/99) of the German
Multicenter Study Group for Adult ALL (GMALL),25 eval-
uating the efficacy of different dosages of dexamethasone,
reported that the “low” dose induction schedules of dex-
amethasone (90 or 120 mg/m2 total dose) showed a simi-
larly good antileukemic efficacy (complete remission rate
of ~80%) as their higher dose schedule (260 mg/m2)
whereas the incidence of early deaths and severe infec-
tions was significantly lower in patients receiving the low
total dose schedule. Although this was not a randomized
trial, the results of this study have already led to a prefer-
ence for dexamethasone instead of prednisolone in
Germany. In the ALL-4 study the patients received a total
dose of 112 mg/m2 dexamethasone during induction,
which is similar to the amount given to the “low” dose
group in the GMALL study. The complete remission rate
was similar (78%) but the incidences of serious infections
and early deaths were higher than those in the patients
receiving the “low” dose schedule of dexamethasone in
the GMALL pilot study. 
Severe toxicity in adults can strongly influence outcome
and thus change the results of steroid therapy. Some data
clearly showed that treatment-related toxicity is signifi-
cantly higher in older patients.26 In addition it seems that
intensive dexamethasone therapy is more immunosup-
pressive than prednisolone and hence more frequently
associated with serious infections in ALL trials.12,27,28
Steroid toxicity in adults could not be compared to that in
children because of the different post-remission treatment
strategies. The majority of adult patients who were eligi-
ble for allogeneic SCT underwent allografting in first com-
plete remission. Most of the children in first complete
remission received intensified chemotherapy courses and
maintenance chemotherapy which are quite tolerable in
this age group of patients. In contrast, allogeneic SCT per-
formed with standard conditioning is still associated with
a high mortality rate, ranging from 15% to 30%.29,30
Recently it was shown that polymorphisms of genes
involved in the corticosteroid response are important pre-
dictors of  steroid toxicity. Glutathione-S-transferase M1
genotype might influence the severity of infection in
childhood ALL.31
In conclusion dexamethasone as a steroid therapy for
adult patients with ALL/LBL at the dose given in the ALL-
4 trial did not show any advantage compared to pred-
nisolone. The toxicity of both drugs during induction ther-
apy and consolidation was similar. 
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Table 4. Grade III-IV toxicity according to first randomization (dexam-
ethasone versus prednisolone) and treatment phase.
Induction course 
Variable Dexamethasone Prednisolone
N=114 (100%) N=112 (100%)
Hemorrhages 6 (5.2) 8 (7.2)
Presence of hyperglycemia 19 (16.7) 12 (10.7)
Insomnia***/neurotoxicity 5 (4.4) 4 (3.6)
Infection 62 (54.4) 67 (59.8)
Others* 41 (36.0) 39 (34.8)
Consolidation course
Variable Dexamethasone Prednisolone
N=68 (100%) N=61 (100%)
Hemorrhages 3 (4.4) 8 (7.2)
Presence of hyperglycemia NA** NA**
Insomnia*** /neurotoxicity 4 (5.9) 3 (6.5)
Infection 57 (83.8) 48 (78.8)
Others* 31 (45.6) 24 (39.3)
*Other clinical relevant complications: nephrotoxicity, cardiotoxicity, etc. **NA: not
applicable (information not collected) ***recorded only during induction.
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